A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description
Shrestha R, Krishnan A, Altice FL, Copenhaver M. A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description. Contemporary Clinical Trials 2015, 44: 95-102. PMID: 26253181, PMCID: PMC4744142, DOI: 10.1016/j.cct.2015.08.002.Peer-Reviewed Original ResearchEvidence-based interventionsHIV risk behaviorsHolistic Health Recovery ProgramSex-related HIV risk behaviorsRisk behaviorsClinical settingCurrent HIV prevention effortsReal-world clinical settingHIV prevention behavioral interventionFormal cost-effectiveness analysisAntiretroviral therapy adherenceNon-inferiority trialHIV prevention effortsAddiction treatment settingsCommon clinical settingsCost-effective relativeCost-effectiveness analysisAddiction treatment programsTherapy adherenceTarget HIVTrial designHIVIntervention DescriptionTreatment settingsUnmet needCost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States
Song DL, Altice FL, Copenhaver MM, Long EF. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLOS ONE 2015, 10: e0116694. PMID: 25658949, PMCID: PMC4320073, DOI: 10.1371/journal.pone.0116694.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsOpioid substitution therapyHIV infectionHIV incidenceHIV prevalenceEvidence-based risk reduction interventionDynamic HIV transmission modelHolistic Health Recovery ProgramBehavioral HIV prevention interventionsFuture HIV incidenceTotal medical costsHIV transmission modelHIV prevention interventionsGeneral adult populationRisk reduction interventionsCost-effectiveness analysisSubstitution therapySexual transmissionHIV programsPrevention interventionsMedical costsTreatment settingsLife yearsReduction interventionsUS population